Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

Significant advances in the management of patients with ulcerative colitis (UC) have been made since the introduction of anti-tumor necrosis factor (TNF)-alpha agents, especially for those who fail or do not tolerate conventional therapies. Two drugs, infliximab first, then adalimumab afterward, sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliese, Daniela, Felice, Carla, Landi, Rosario, Papa, Alfredo, Guidi, Luisa, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745853/
https://www.ncbi.nlm.nih.gov/pubmed/26893582
http://dx.doi.org/10.2147/DHPS.S62649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745853/
https://www.ncbi.nlm.nih.gov/pubmed/26893582
http://dx.doi.org/10.2147/DHPS.S62649

Ejemplares similares